A court battle between two of the nation’s largest biotechs — Regeneron Pharmaceuticals and Amgen — is testing the legal limits of how far drugmakers can go in using patents to thwart ...

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Options Coach’s Substack by Taylor Selden. In this ...

A court battle between two of the nation’s largest biotechs — Regeneron Pharmaceuticals and Amgen — is testing the legal limits of how far drugmakers can go in using patents ...

Oct 4 - Biotech company Regeneron Pharmaceuticals (REGN.O), opens new tab lost a bid on Friday to be held immune from allegations that it misused a patented protein while testing a COVID-19 ...

Regeneron Pharmaceuticals has settled allegations that it misused a patented protein to test its COVID-19 treatment REGEN-COV, according to filings in New York federal court.

Regeneron struck back with its suit in 2022, arguing that the proposed copycat steps on 24 of its patents. The complaint was later trimmed to three, according to Bloomberg .

Update 3:15pm: Adds Regeneron comment, updates shares. Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 4.5% after a judge denied the company's motion for a preliminary injunction to block an Amgen ...

Regeneron (REGN) secures a win in a patent suit against Viatris (VTRS) over Eylea patents, leading to a 1.6% increase in stock value.

In its complaint against Amgen, which was filed in January of this year, Regeneron listed 32 patents it claimed were infringed. Upon the decision, the company immediately filed an appeal.

Regeneron Pharmaceuticals said it is working to determine a path forward for its treatment of several retinal conditions after the Food and Drug Administration said it didn't agree with the ...